BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38627415)

  • 1. TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors.
    McAvera RM; Morgan JJ; Herrero AB; Mills KI; Crawford LJ
    Sci Rep; 2024 Apr; 14(1):8797. PubMed ID: 38627415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein.
    Kulkarni A; Oza J; Yao M; Sohail H; Ginjala V; Tomas-Loba A; Horejsi Z; Tan AR; Boulton SJ; Ganesan S
    J Biol Chem; 2013 Nov; 288(45):32357-32369. PubMed ID: 23926104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
    Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ
    Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
    Soni A; Siemann M; Pantelias GE; Iliakis G
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
    Wang M; Wu W; Wu W; Rosidi B; Zhang L; Wang H; Iliakis G
    Nucleic Acids Res; 2006; 34(21):6170-82. PubMed ID: 17088286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma.
    Caracciolo D; Scionti F; Juli G; Altomare E; Golino G; Todoerti K; Grillone K; Riillo C; Arbitrio M; Iannone M; Morelli E; Amodio N; Di Martino MT; Rossi M; Neri A; Tagliaferri P; Tassone P
    Haematologica; 2021 Jan; 106(1):185-195. PubMed ID: 32079692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
    Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
    Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability.
    Herrero AB; San Miguel J; Gutierrez NC
    PLoS One; 2015; 10(3):e0121581. PubMed ID: 25790254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
    Jiang Y; Yam JC; Chu WK
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in cancer therapy using PARP inhibitors.
    Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
    Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
    Park Y; Chui MH; Suryo Rahmanto Y; Yu ZC; Shamanna RA; Bellani MA; Gaillard S; Ayhan A; Viswanathan A; Seidman MM; Franco S; Leung AKL; Bohr VA; Shih IM; Wang TL
    Clin Cancer Res; 2019 Sep; 25(18):5584-5594. PubMed ID: 31196855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
    Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
    Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
    Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
    PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
    Xiong T; Wei H; Chen X; Xiao H
    Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks.
    Ma J; Zhou Y; Pan P; Yu H; Wang Z; Li LL; Wang B; Yan Y; Pan Y; Ye Q; Liu T; Feng X; Xu S; Wang K; Wang X; Jian Y; Ma B; Fan Y; Gao Y; Huang H; Li L
    Nat Commun; 2023 Mar; 14(1):1810. PubMed ID: 37002234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
    Becker JR; Cuella-Martin R; Barazas M; Liu R; Oliveira C; Oliver AW; Bilham K; Holt AB; Blackford AN; Heierhorst J; Jonkers J; Rottenberg S; Chapman JR
    Nat Commun; 2018 Dec; 9(1):5406. PubMed ID: 30559443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-strand break repair-adox: Restoration of suppressed double-strand break repair during mitosis induces genomic instability.
    Terasawa M; Shinohara A; Shinohara M
    Cancer Sci; 2014 Dec; 105(12):1519-25. PubMed ID: 25287622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
    Shenoy TR; Boysen G; Wang MY; Xu QZ; Guo W; Koh FM; Wang C; Zhang LZ; Wang Y; Gil V; Aziz S; Christova R; Rodrigues DN; Crespo M; Rescigno P; Tunariu N; Riisnaes R; Zafeiriou Z; Flohr P; Yuan W; Knight E; Swain A; Ramalho-Santos M; Xu DY; de Bono J; Wu H
    Ann Oncol; 2017 Jul; 28(7):1495-1507. PubMed ID: 28383660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.